BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 31, 2024
Breaking News: Topic alerts now available for all BioWorld subscribers
See today's BioWorld Science
Home
» CSPC’s bispecific fusion protein drug JMT-106 gains US IND clearance for GPC3-positive solid tumors
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
CSPC’s bispecific fusion protein drug JMT-106 gains US IND clearance for GPC3-positive solid tumors
Jan. 16, 2024
No Comments
CSPC Pharmaceutical Group Ltd. has announced FDA approval of an IND application for JMT-106, a bispecific fusion protein drug, for glypican-3 (GPC3)-positive solid tumors.
BioWorld Science
Regulatory
Cancer
Immuno-oncology
FDA
IND
